Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia.
We show how the loss of activity of the translation initiation factor EIF5A2-either through gene hypermethylation or pharmacologic inhibition of its highly specific hypusine post-translational modific
APA
Crespo-García E, Quero-Dotor C, et al. (2026). Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia.. British journal of haematology, 208(4), 1437-1442. https://doi.org/10.1111/bjh.70339
MLA
Crespo-García E, et al.. "Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia.." British journal of haematology, vol. 208, no. 4, 2026, pp. 1437-1442.
PMID
41606290
Abstract
We show how the loss of activity of the translation initiation factor EIF5A2-either through gene hypermethylation or pharmacologic inhibition of its highly specific hypusine post-translational modification-induces venetoclax sensitivity in acute myeloid leukaemia (AML) cells.
MeSH Terms
Humans; Leukemia, Myeloid, Acute; Bridged Bicyclo Compounds, Heterocyclic; Sulfonamides; Peptide Initiation Factors; Eukaryotic Translation Initiation Factor 5A; RNA-Binding Proteins; Epigenesis, Genetic; Gene Silencing; Cell Line, Tumor; DNA Methylation; Antineoplastic Agents; Neoplasm Proteins